PCYC - Pharmawert mit 100 % Reboundpotential - - 500 Beiträge pro Seite

[the key]

Aktueller Kurs: $3,91 KZ : $8,00

Kurs ist von $9,48 bis auf $3,26 gefallen,weil ein Lungenkrebsmedikament nicht die 3. Phase bestanden hat.
Pharmacyclics wird Xcytrin in drei weiteren Versuchen testen.
Desweiteren stehen versch. andere Medikamente in unterschiedlichen Phasen in der Pipeline.
Meiner Meinung ist dieses Unternehmen ein genaueren Blick wert.

Yahoo NEWS:
http://finance.yahoo.com/q?s=pcyc
Chart:
http://stockcharts.com/gallery/?PCYC


Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer, atherosclerosis and other diseases. The company`s products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at http://www.pharmacyclics.com. Pharmacyclics®, Xcytrin® and the "pentadentate" logo® are registered trademarks of Pharmacyclics, Inc.

[the key]

Kurs FSE 15 Min verzögert:

Realtimechart PCYC Nasdaq

[the key]

Homepage des Unternehmens:

http://www.pharmacyclics.com/

aktueller Kurs $4,15

[the key]

[posting]19.619.346 von the key am 09.01.06 17:35:23[/posting]http://www.pharmacyclics.com/

[the key]

Schlusskurs $4,20

[nkelchen]

[posting]19.628.330 von the key am 10.01.06 02:40:05[/posting]

bin seit 3,54 dabei -
und hatte schon viel Spass.

Gruss
nk

[the key]

[posting]19.631.742 von nkelchen am 10.01.06 09:40:08[/posting]Bin zwar erst bei $3,80 rein aber immerhin

[nkelchen]

[posting]19.644.416 von the key am 10.01.06 21:33:48[/posting]

war wohl eine nötige Korrektur-
mini Gap damit geschlossen.



nk

[nkelchen]

gerade auf 4,58



hier geht die Post ab...
nk

[nkelchen]

wenn wir die 4,59 breaken, gibt es kein Halten mehr.
Dann sind die 5 ganz nahe!!

nk

[nkelchen]

[posting]19.659.713 von nkelchen am 11.01.06 17:53:30[/posting]

Yepp

4,77

nk

[the key]

Hi ,

bin grad rein

Sieht gut aus RT

Detailed Quote Snapshot 01/11/2006 02:12 PM
Last:
4.73

pcyc - PHARMACYCLICS INC
Change:
+0.56

% Change:
+13.43%

High:
4.82

Low:
4.3

Volume:
1,137,587

[the key]

Detailed Quote Snapshot 01/11/2006 02:41 PM
Last:4.78
pcyc - PHARMACYCLICS INC
High:4.82 Low:4.30 Volume:1,206,145

[the key]

Schlusskurs: $4,98

[nkelchen]

[posting]19.664.678 von the key am 11.01.06 22:11:01[/posting]

[WissenMacht]

[nkelchen]

Market Information

Ticker PCYC

Last Sale $ 4.99

Change Net $ + 0.82


Change % 19.66%

Share Volume 1,576,800

More Info >>


Investor Contact
Pharmacyclics Inc.
995 East Arques Avenue
Sunnyvale, California
94085
Phone: [phone]
Fax: [phone]

[e-mail]

[nkelchen]

http://64.233.183.104/search?q=cache:EDAoS9NGhJIJ:www.phrma.…

[nkelchen]

nk

[the key]

Schlusskurs : $4,83

[the key]

[posting]19.686.276 von the key am 13.01.06 00:47:49[/posting]Schlusskurs: $5,01

[nkelchen]

[posting]19.704.888 von the key am 14.01.06 01:41:21[/posting]

Heute ein SK über 4,80
und wir können uns auf steigende Kurse freuen...



nk

[the key]

Schlusskurs $5,03

[nkelchen]

[posting]19.794.614 von the key am 20.01.06 01:22:16[/posting]

mit minus 8% gestartet - und gerade schon im Plus!!

Pharmacyclics Reports Second Quarter Financial Results
1/26/2006 7:31:16 AM










SUNNYVALE, Calif., Jan 26, 2006 /PRNewswire-FirstCall via COMTEX/ -- Pharmacyclics, Inc. (PCYC) today reported financial results for its second fiscal quarter ended December 31, 2005. The net loss for the second quarter of fiscal 2006, as reported in accordance with U.S. generally accepted accounting principles (GAAP), was $9.9 million, or $0.50 per share, compared to a net loss of $7.8 million, or $0.40 per share, in the second quarter of fiscal 2005. Second quarter of fiscal 2006 non-GAAP pro forma net loss was $8.0 million, or $0.40 per share. The difference between GAAP net loss and non-GAAP pro forma net loss for the second quarter of fiscal 2006 is the result of $1.9 million of stock-based compensation expense recorded in accordance with the adoption of SFAS 123R as of July 1, 2005.







Total GAAP operating expenses were $10.4 million in the second quarter of fiscal 2006 compared to $8.2 million for the second quarter of fiscal 2005, an increase of $2.2 million. This increase included $1.9 million in stock-based compensation expense and approximately $0.6 million associated with increased personnel and consulting costs to support the company`s operations, which was offset by a $0.5 million reduction in outside clinical trial costs due to the conclusion of the company`s pivotal Phase 3 trial with Xcytrin(R).

Pharmacyclics also reported its financial results for the six months ended December 31, 2005. The net loss, on a GAAP basis, for the six months ended December 31, 2005 was $20.1 million, or $1.01 per share, compared to a net loss of $15.1 million, or $0.77 per share, for the six months ended December 31, 2004. The non-GAAP pro forma net loss for the six months ended December 31, 2005 was $16.6 million or $0.84 per share, compared to a non-GAAP pro forma net loss of $15.1 million, or $0.77 per share for the six months ended December 31, 2004.

As of December 31, 2005, the company`s cash, cash equivalents and marketable securities totaled $56.4 million compared to $71.9 million as of June 30, 2005.

Note: Pharmacyclics` non-GAAP net loss and non-GAAP net loss per share exclude recurring expenses associated with stock-based compensation expense. The differences in non-GAAP and GAAP numbers are reconciled in the tables below.

Reconciliation of GAAP to Pro Forma Diluted Net Loss (in thousands):

Three Three Six Six
Months Months Months Months
Ended Ended Ended Ended
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2005 2004 2005 2004
GAAP Diluted Net Loss $(9,890) $(7,787) $(20,091) $(15,090)
Plus: Stock-based compensation
expense 1,911 7 3,508 10
Non-GAAP Pro Forma Diluted Net Loss $(7,979) $(7,780) $(16,583) $(15,080)

About Xcytrin


Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox active drug that disrupts redox dependent pathways in cells and inhibits oxidative stress related proteins. Its multifunctional mode of action provides the opportunity to be used in a broad range of cancers. Xcytrin is paramagnetic and produces an intense MRI signal which can be used to image tumors. Pharmacyclics has been granted Fast-Track status by the U.S. Food and Drug Administration (FDA) for Xcytrin for the treatment of brain metastases (cancer that has spread to the brain from another part of the body) in non-small cell lung cancer (NSCLC) patients. Xcytrin is currently under investigation in several Phase 1 and Phase 2 clinical trials in various cancers evaluating its use as a single agent and in combination with chemotherapy and/or radiation therapy.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer, atherosclerosis and other diseases. The company`s products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results, including analyses of data from preclinical and clinical studies, including results from our SMART trial, clinical development plans and product development activities are forward- looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward- looking statements. Factors that could affect actual results include risks associated with the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in and unanticipated increases in costs related to our preclinical studies and clinical trials; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company`s reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the year ended June 30, 2005 and its quarterly report on Form 10-Q for the period ended September 30, 2005. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Pharmacyclics, Inc.
(a development stage enterprise)
Condensed Statements of Operations
(unaudited) (in thousands, except per share data)

Three Months
Ended December 31,
2005 2004
Non-GAAP Non-
GAAP[1] Difference [2] GAAP[1] Difference GAAP[2]
Operating expenses:
Research and
development $6,698 $(965)[3] $5,733 $6,277 $(7)[3] $6,270
General and
administrative 3,686 (946)[3] 2,740 1,952 -- [3] 1,952
Total
operating
expenses 10,384 (1,911) 8,473 8,229 (7) 8,222
Loss from
operations (10,384) 1,911 (8,473) (8,229) 7 (8,222)
Interest and other
income, net 494 -- 494 442 -- 442
Net loss $(9,890) $1,911 $(7,979) $(7,787) $7 $(7,780)

Basic and diluted
net loss per
share $(0.50) $(0.10) $(0.40) $(0.40) $-- $(0.40)
Shares used to
compute basic and
diluted net loss
per share 19,878 -- 19,878 19,707 -- 19,707


Six Months
Ended December 31,
2005 2004
Non-GAAP Non-
GAAP[1] Difference [2] GAAP[1] Difference GAAP[2]
Operating
expenses:
Research and
development $14,002 $(1,747)[3] $12,255 $12,386 $(10)[3] $12,376
General and
administrative 7,071 (1,761)[3] 5,310 3,580 -- 3,580
Total operating
expenses 21,073 (3,508) 17,565 15,966 (10) 15,956
Loss from
operations (21,073) 3,508 (17,565) (15,966) 10 (15,956)
Interest and other
income, net 982 -- 982 876 -- 876
Net loss $(20,091) $3,508 $(16,583) $(15,090) $10 $(15,080)

Basic and diluted
net loss per
share $(1.01) $(0.17) $(0.84) $(0.77) $-- $(0.77)
Shares used to
compute basic
and diluted net
loss per share 19,854 -- 19,854 19,678 -- 19,678

[1] Reflects operating results in accordance with U.S. generally accepted
accounting principles (or GAAP).
[2] Non-GAAP amounts exclude stock-based compensation expense.
[3] Represents stock-based compensation expense.


Pharmacyclics, Inc.
(a development stage enterprise)
Condensed Balance Sheets
(unaudited, in thousands)

December 31, June 30,
2005 2005
Assets
Cash, cash equivalents and marketable securities $56,367 $71,899
Other current assets 1,247 1,254
Total current assets 57,614 73,153
Property and equipment, net 815 884
Other noncurrent assets 527 527
$58,956 $74,564
Liabilities and stockholders` equity
Current liabilities $4,988 $4,473
Long-term obligations 93 97
Stockholders` equity 53,875 69,994
$58,956 $74,564


SOURCE Pharmacyclics, Inc.

Leiv Lea of Pharmacyclics, Inc., [phone]; or Carolyn Bumgardner Wang of
WeissComm Partners, [phone], for Pharmacyclics, Inc.

http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.


nk

[the key]

[posting]19.895.159 von nkelchen am 26.01.06 17:52:04[/posting]Bin mal gespannt wie es heute weitergeht

[nkelchen]

[posting]19.910.640 von the key am 27.01.06 14:08:37[/posting]

wenn ich ehrlich bin,
bei den Zahlen dreht sich mir der Magen.
Wäre das nicht ein Experiment, ich habe auch NABI, SCLN und
RIGL im Depo, ich würde keinen normalen Biotech Wert anfassen.
Aber hier geht es mir nur um den Chart und den möglichen Rebound.

Gruss
nk

[the key]

[posting]19.910.719 von nkelchen am 27.01.06 14:12:18[/posting]Bin auch wg der Charttechnik investiert.
Habe aber noch eine Empfehlung zu PCYC gefunden

Und mutig sind wir allemal

http://www.ariva.de/news/article.m?id=2004165&secu=2982

[nkelchen]

[posting]19.910.890 von the key am 27.01.06 14:20:57[/posting]

"Global Insider Investing".

ja nee is klar...

nk

[nkelchen]

nk

[the key]

Hot Stocks Investor - Pharmacyclics für Spekulative

12:20 30.01.06

Nach Ansicht der Experten von "Hot Stocks Investor" eignet sich die Aktie von Pharmacyclics (ISIN US7169331060/ WKN 904042) für spekulativ orientierte Anleger.

Das Unternehmen habe im Dezember eingestehen müssen, dass Phase III-Tests mit dem Wirkstoff Xcytrin gegen Lungenkrebs keine statistisch bedeutenden Ergebnisse geboten habe. Der Kurs sei daraufhin auf Tiefs von gerade noch gut 3 USD nach unten gestürzt. Der Markt habe dabei die Aussagen der Unternehmensführung ignoriert, denen zufolge die Ergebnisse deutlich differenziert zu beurteilen seien, da in bestimmten Einzelfällen eine sehr intensive Reponse auf das Präparat festgestellt worden sei und die Story damit noch keinesfalls vorüber wäre.

Bemerkenswert sei, dass der Beneficial Owner Robert W. Duggan nun im Januar schrittweise ein Paket von immerhin 123.000 Pharmacyclics-Aktien erworben habe, wofür er eine halbe Million USD bezahlt habe.

Vor diesem Hintergrund empfehlen die Experten von "Hot Stocks Investor" spekulativen Anlegern bei der Pharmacyclics-Aktie einzusteigen.

[the key]

SK $4,92

[the key]

Wenn wir die $5,00 endlich nehmen ,dann geht es wieder Richtung Norden!!!

[nkelchen]

[posting]20.029.294 von the key am 03.02.06 14:43:37[/posting]

so ist es!
Der Chart(Fahne)könnte Das auch hergeben.
Allerdings sehen die Indikatoren meiner Meinung nach eher schlecht aus.
Vielleicht gelingt ja der Sprung auf die 5,
dann heisst es aber erst einmal neue Kräfte sammeln.



mer mal..
Gruss
nk

[the key]

[the key]

Auf TH heute geschlossen $4,72 Volumen 166,198

[the key]

[the key]

[the key]

Aktie steht kurz vor dem Durchbruch des ersten Abwärtstrendkanals!!!

[nkelchen]

[posting]20.441.285 von the key am 01.03.06 13:12:05[/posting]

sehr gute Charts!

Gruss
nk

[the key]

[posting]20.441.448 von nkelchen am 01.03.06 13:21:09[/posting]Morgen folgt der 2. Anlauf

[nkelchen]

[posting]20.455.437 von the key am 01.03.06 23:41:31[/posting]

SCLN ist Gestern durch die 2,50 geflogen,
auch RIGL hat die Tage den Durchbruch geschafft.

Gruss
nk

[nkelchen]

da geht zur Zeit nix!



die 4,80 wurde gekonnt zugemauert.

Gruss
nk

[the key]

[posting]20.471.931 von nkelchen am 02.03.06 18:54:33[/posting]Kommt Zeit kommt Rat

[the key]

[the key]

Antwort auf Beitrag Nr.: 20.625.472 von the key am 10.03.06 23:41:46

READY to GO!!!

[nkelchen]

Antwort auf Beitrag Nr.: 20.926.740 von the key am 23.03.06 20:07:55

Die Umsätze sind echt ein Witz.
20-30-40k am Tag
Wenn hier einmal Volumen rein kommt, fliegt
das Teil durch die Decke!

nk

[the key]

Antwort auf Beitrag Nr.: 21.034.108 von nkelchen am 31.03.06 19:23:28

Also ich denke es wird nicht mehr lange dauern bis der Deckel wegfliegt

[the key]

[nkelchen]

Antwort auf Beitrag Nr.: 21.202.287 von the key am 14.04.06 13:20:48

Nächster Halt 6,50!

frohe Ostern!

nk

[the key]

Antwort auf Beitrag Nr.: 21.202.408 von nkelchen am 14.04.06 13:42:30

Danke,

es geht zwar lanfsam aber beständig Richtung Norden

[nkelchen]

Es hellt sich wieder auf....


Press Release Source: Pharmacyclics, Inc.

Pharmacyclics to Submit New Drug Application for Xcytrin(R) for Treatment of Lung Cancer Patients With Brain Metastases
Tuesday May 9, 7:30 am ET
New Analyses and Additional Data from Phase 3 SMART Trial to be Presented at ASCO 2006


SUNNYVALE, Calif., May 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC - News) today announced that the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) to market Xcytrin® (motexafin gadolinium) Injection for the treatment of non-small cell lung cancer (NSCLC) patients with brain metastases (i.e., lung cancer that has spread to the brain from another part of the body).
ADVERTISEMENT


The company also announced that new analyses and additional data from its Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta. Details on the oral presentation are as follows:

Abstract #7014: "Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a Phase 3 trial," Minesh P. Mehta, M.D., Dept. of Human Oncology, University of Wisconsin, Madison, Saturday, June 3, 2006, 5:30 - 5:45 p.m.

The presentation will be followed by a discussion by Laurie E. Gaspar, M.D., Professor and Chair of Radiation Oncology at the University of Colorado.

The SMART trial was conducted at 94 centers in North America, Europe and Australia and enrolled 554 patients with brain metastases from NSCLC. This randomized, controlled Phase 3 trial compared the safety and efficacy of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin. The primary endpoint of the study was time to neurologic progression as determined by a blinded events review committee.

"We plan to file an NDA for Xcytrin primarily based on the data from our pivotal SMART trial," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "New data from the SMART trial, which will be included in the NDA filing, will be presented and discussed at ASCO. We anticipate filing the Xcytrin NDA by the end of 2006."

About Xcytrin

Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress related proteins. Its multifunctional mode of action provides the opportunity to be used in a broad range of cancers. Xcytrin has been granted Fast Track designation by the FDA for use in the treatment of lung cancer brain metastases. This designation is reserved for new drugs that demonstrate the potential to address an unmet medical need and are intended for the treatment of a serious or life-threatening condition.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer, atherosclerosis and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical testing in lung cancer brain metastases and several Phase 1 and Phase 2 clinical trials are ongoing with Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. Pharmacyclics has other product candidates in earlier-stage development for cancer and inflammatory diseases. More information about the company, its technology, and products can be found at www.pharmacyclics.com. Pharmacyclics®, Xcytrin® and the "pentadentate" logo® are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, including results from our SMART trial, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "potential," "project," "believe," "will," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in and unanticipated increases in costs related to our preclinical studies and clinical trials; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the outcome of our discussions with the FDA; our ability to prepare and submit an NDA on a timely basis or at all; the possibility that the FDA refuses to accept any NDA we submit; the possibility that additional data or studies may be required before the NDA is accepted for filing or approved by the FDA; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its quarterly report on Form 10-Q for the period ended December 31, 2005. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Source: Pharmacyclics, Inc.

[nkelchen]

Antwort auf Beitrag Nr.: 21.491.070 von nkelchen am 09.05.06 16:11:08

und tschüss -
war ne schöne Zeit.
nk

[the key]

[the key]

Wow die Aktien war ja schon bei $ 6.15 vor ein paar Tagen.Ist ja nicht mehr weit bis zum Kz. braucht halt nur etwas Geduld

[GerdKill]

heute wird ja wieder einiges geboten!